
    
      GSK Biologicals has developed a meningococcal conjugate vaccine (GSK134612). This candidate
      vaccine has been shown to be well tolerated and immunogenic in toddlers.

      The purpose of this study is to evaluate the antibody persistence at approximately 1 year, 3
      years and 5 years post-administration of one dose or two doses of GlaxoSmithKline (GSK)
      Biologicals' meningococcal vaccine GSK134612 when given to healthy toddlers 9-12 months of
      age. To evaluate, the safety and immunogenicity of a booster dose of GSK134612 administered
      to all eligible subjects at 5 years after the primary vaccination. To evaluate the safety and
      immunogenicity in a new group of subjects aged 5-6 years (naive control group) who will
      receive a single dose of vaccine GSK134612.
    
  